Package Leaflet: Information for the User
Vizarsin 100 mg Film-Coated Tablets
sildenafil
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Vizarsin contains the active substance sildenafil, which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by dilating the blood vessels in the penis, allowing blood to flow in when you are sexually stimulated. Vizarsin will only help you to get an erection if you are sexually stimulated.
Vizarsin is indicated for the treatment of erectile dysfunction in adult men, sometimes referred to as impotence. This occurs when a man cannot get or maintain an erection that is sufficient for satisfactory sexual activity.
Do not take Vizarsin
Warnings and precautions
Consult your doctor or pharmacist before taking Vizarsin:
It is not recommended to use Vizarsin in combination with any other oral or local treatment for erectile dysfunction.
You must not take Vizarsin with treatments for pulmonary arterial hypertension (PAH) that contain sildenafil or any other PDE5 inhibitor.
You must not take Vizarsin if you do not have erectile dysfunction.
The use of Vizarsin is not indicated in women.
Special considerations in patients with kidney or liver problems
You should inform your doctor if you have kidney or liver problems. Your doctor may decide to reduce your dose.
Children and adolescents
The use of Vizarsin is not indicated in persons under 18 years of age.
Using Vizarsin with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Vizarsin tablets may interfere with some medicines, especially those used to treat chest pain. In the event of a medical emergency, you should inform your doctor, pharmacist, or nurse that you are taking Vizarsin and when you took it. Do not take Vizarsin with other medicines unless your doctor advises you to.
You must not take Vizarsin if you are taking medicines called nitrates, as the combination may lead to a dangerous decrease in your blood pressure. Always inform your doctor, pharmacist, or nurse if you are taking any of these medicines, often used to relieve angina pectoris (or "chest pain").
You must not take Vizarsin if you are taking medicines called nitric oxide donors, such as amyl nitrate ("poppers"), as the combination may also lead to a dangerous decrease in your blood pressure. Inform your doctor or pharmacist if you are taking riociguat.
If you are taking medicines known as protease inhibitors, such as those used to treat HIV, your doctor may recommend that you start with the lowest dose (25 mg) of Vizarsin.
Some patients who are taking an alpha-blocker, a medicine used to treat high blood pressure or an enlarged prostate, may experience dizziness or lightheadedness that can be caused by a decrease in blood pressure when sitting or standing up quickly. Some patients have experienced these symptoms when taking Vizarsin with alpha-blockers. This is more likely to happen within 4 hours after taking Vizarsin. To minimize the likelihood of these symptoms, you should be taking your daily dose of the alpha-blocker regularly before starting Vizarsin. Your doctor may advise you to start with the lower dose (25 mg) of Vizarsin.
Using Vizarsin with food, drinks, and alcohol
Vizarsin can be taken with or without food. However, you may notice that Vizarsin takes a little longer to work if you take it with a large meal.
Consuming alcohol may temporarily impair your ability to get an erection. Therefore, to get the maximum benefit from the medicine, it is advised not to drink large amounts of alcohol before taking Vizarsin.
Pregnancy, breastfeeding, and fertility
The use of Vizarsin is not indicated in women.
Driving and using machines
Vizarsin can cause dizziness and affect vision. You should know how you react to Vizarsin before driving or operating machinery.
Vizarsin contains lactose and sodium
If your doctor has told you that you have an intolerance to some sugars, consult him before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are unsure, consult your doctor or pharmacist.
The recommended starting dose is 50 mg.
You must not take Vizarsin more than once a day.
You should take Vizarsin about one hour before you plan to have sex. Swallow the tablet whole with a glass of water.
If you notice that the effect of Vizarsin is too strong or too weak, tell your doctor or pharmacist.
Vizarsin will only help you to get an erection if you are sexually stimulated. The time Vizarsin takes to work varies from person to person, but it normally takes between 30 minutes and 1 hour. The effect of Vizarsin may be delayed if you take it with a large meal.
If Vizarsin does not help you to get an erection, or if the erection does not last long enough to complete sexual intercourse, consult your doctor.
If you take more Vizarsin than you should
You may experience an increase in side effects and their severity. Doses above 100 mg do not increase efficacy.
You must not take more tablets than your doctor prescribes.
Contact your doctor if you have taken more tablets than you should.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects reported with Vizarsin are usually mild to moderate and short-lived.
If you experience any of the following serious side effects, stop taking Vizarsin and seek medical attention immediately:
Symptoms include sudden wheezing, difficulty breathing or dizziness, swelling of the eyelids, face, lips or throat.
If this occurs during or after intercourse:
If you have an erection that lasts more than 4 hours, you should contact your doctor immediately.
Symptoms can include severe skin peeling and swelling, blistering of the mouth, genitals, and around the eyes, as well as fever.
Other side effects:
Very common(may affect more than 1 in 10 people): headache.
Common(may affect up to 1 in 10 people): nausea, facial flushing, hot flush (including a feeling of warmth), indigestion, abnormal color perception, blurred vision, visual disturbance, nasal congestion, and dizziness.
Uncommon(may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, eye discharge/red eyes, eye pain, seeing flashes of light, increased sensitivity to light, watery eyes, palpitations, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy nose (including symptoms such as runny nose, sneezing, and nasal congestion), abdominal pain, gastroesophageal reflux disease (including symptoms such as heartburn), blood in urine, pain in arms or legs, nosebleeds, feeling hot, and feeling tired.
Rare(may affect up to 1 in 1,000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decrease in blood flow to parts of the brain, feeling of pressure in the throat, numbness in the mouth, bleeding in the back of the eye, double vision, decreased sharpness of vision, abnormal sensation in the eye, eye swelling or eyelid swelling, small particles or spots in the vision, seeing halos around lights, dilation of the pupil, change in color of the white of the eye, bleeding from the penis, presence of blood in the semen, dry nose, swelling inside the nose, feeling irritable, and sudden decrease or loss of hearing.
During post-marketing experience, unstable angina (heart disease) and sudden death have been reported rarely. It should be noted that most men who experienced these side effects had pre-existing heart disease before taking this medicine. It is not possible to determine whether these side effects were directly related to Vizarsin.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Vizarsin Composition
Tablet core: | microcrystalline cellulose (E460), hydrogenated calcium phosphate, sodium croscarmellose, hypromellose (E464), magnesium stearate (E470b). |
Film coating: | film coating: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518). |
See section 2 "Vizarsin contains lactose and sodium".
Product Appearance and Package Contents
Vizarsin 100 mg film-coated tablets are white, oblong, and engraved with "100" on one side.
Vizarsin 100 mg film-coated tablets are available in packs of 1 film-coated tablet in a blister pack and also in packs of 4 x 1, 8 x 1, or 12 x 1 film-coated tablet in perforated unit dose blisters.
Only some pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
For further information on this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien KRKA Belgium, SA. Tél/Tel: + 32 (0) 487 50 73 62 | Lietuva UAB KRKA Lietuva Tel: + 370 5 236 27 40 |
Luxembourg/Luxemburg KRKA Belgium, SA. Tél/Tel: + 32 (0) 487 50 73 62 (BE) | |
Ceská republika KRKA CR, s.r.o. Tel: + 420 (0) 221 115 150 | Magyarország KRKA Magyarország Kereskedelmi Kft. Tel.: + 36 (1) 355 8490 |
Danmark KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE) | Malta
Tel: + 356 21 445 885 |
Deutschland TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 | Nederland KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) |
Eesti KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 658 | Norge KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE) |
Ελλáδα KRKA ΕΛΛΑΣ ΕΠΕ Τηλ: + 30 2100101613 | Österreich KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 300 |
España KERN PHARMA, S.L. Tel: + 34 93 700 25 25 | Polska KRKA-POLSKA Sp. z o.o. Tel.: + 48 (0)22 573 7500 |
France KRKA France Eurl Tél: + 33 (0)1 57 40 82 25 | Portugal KRKA Farmacêutica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 650 |
Hrvatska KRKA - FARMA d.o.o. Tel: + 385 1 6312 100 | România KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 05 |
Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3710 | Slovenija KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 100 |
Ísland LYFIS ehf. Sími: + 354 534 3500 | Slovenská republika KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 501 |
Italia KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8841 | Suomi/Finland KRKA Finland Oy Puh/Tel: + 358 20 754 5330 |
Κúπρος KI.PA. (PHARMACAL) LIMITED Τηλ: + 357 24 651 882 | Sverige KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Latvija KRKA Latvija SIA Tel: + 371 6 733 86 10 | United Kingdom (Northern Ireland) KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3710 |
Date of Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.